{"DataElement":{"publicId":"2825164","version":"1","preferredName":"Four-Hydroxytamoxifen Laboratory Test Name","preferredDefinition":"The name that describes the tamoxifen metabolite with both estrogenic and anti-estrogenic effects.","longName":"FOUR_OHT_LAB_TST_NM","context":"DCP","contextVersion":"1","DataElementConcept":{"publicId":"2825157","version":"1","preferredName":"4-Hydroxytamoxifen Laboratory Procedure","preferredDefinition":"Information pertaining to tamoxifen metabolite with both estrogenic and anti-estrogenic effects.  4-hydroxytamoxifen has a higher affinity for the estrogen receptor than tamoxifen, and functions as an antagonist in breast cancer cells.","longName":"4-OHT_LAB_PROC","context":"DCP","contextVersion":"1","ObjectClass":{"publicId":"2825155","version":"1","preferredName":"4-Hydroxytamoxifen","preferredDefinition":"A tamoxifen metabolite with both estrogenic and anti-estrogenic effects.  4-hydroxytamoxifen has a higher affinity for the estrogen receptor than tamoxifen, and functions as an antagonist in breast cancer cells. (NCI04)","longName":"C975","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Afimoxifene","conceptCode":"C975","definition":"A tamoxifen metabolite with both estrogenic and anti-estrogenic effects.  Afimoxifene has a higher affinity for the estrogen receptor than tamoxifen, and functions as an antagonist in breast cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"608AA882-62A4-A8D3-E040-BB89AD4315E1","latestVersionIndicator":"Yes","beginDate":"2009-01-15","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-01-15","modifiedBy":"ONEDATA","dateModified":"2009-01-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2486250","version":"1","preferredName":"Test","preferredDefinition":"A procedure for critical evaluation; a means of determining the presence, quality, or truth of something.","longName":"C25294","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Laboratory Procedure","conceptCode":"C25294","definition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"15A9DA1A-D89C-6C6C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-07","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-06-07","modifiedBy":"ONEDATA","dateModified":"2006-06-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2182370","version":"1","preferredName":"Procedures","preferredDefinition":"Tests, examinations, evaluations used to determine a subject's status or response to intervention.  ","longName":"PROCEDURES","context":"CCR","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D7049CF8-1252-211C-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-04-01","endDate":null,"createdBy":"DWARZEL","dateCreated":"2004-04-01","modifiedBy":"REEVESD","dateModified":"2004-09-24","changeDescription":"Created initially to support CCR value domain for CTMS. ","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"DCP:Division of Cancer Prevention","workflowStatus":"RELEASED","registrationStatus":"Application","id":"608AA882-62B2-A8D3-E040-BB89AD4315E1","latestVersionIndicator":"Yes","beginDate":"2009-01-15","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-01-15","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2825159","version":"1","preferredName":"Four-Hydroxytamoxifen Name","preferredDefinition":"The name that describes the tamoxifen metabolite with both estrogenic and anti-estrogenic effects.  4-hydroxytamoxifen has a higher affinity for the estrogen receptor than tamoxifen, and functions as an antagonist in breast cancer cells.","longName":"FOUR_OHT_NM","context":"DCP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"8","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"E Isomer","valueDescription":"E Isomer","ValueMeaning":{"publicId":"3140707","version":"1","preferredName":"E Isomer","longName":"3140707","preferredDefinition":"A double bond with its highest priority side groups on opposite sides.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"E Isomer","conceptCode":"C92193","definition":"A double bond with its highest priority side groups on opposite sides.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"90D9E57A-FBDE-41F9-E040-BB89AD434558","latestVersionIndicator":"Yes","beginDate":"2010-09-22","endDate":null,"createdBy":"MAESKEB","dateCreated":"2010-09-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"90D9E57A-FBF6-41F9-E040-BB89AD434558","beginDate":"2009-01-15","endDate":null,"createdBy":"MAESKEB","dateCreated":"2010-09-22","modifiedBy":"ONEDATA","dateModified":"2010-09-22","deletedIndicator":"No"},{"value":"Z Isomer","valueDescription":"Z Isomer","ValueMeaning":{"publicId":"3140708","version":"1","preferredName":"Z Isomer","longName":"3140708","preferredDefinition":"A double bond with its highest priority side groups on the same side.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Z Isomer","conceptCode":"C92194","definition":"A double bond with its highest priority side groups on the same sides.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"90D9E57A-FC03-41F9-E040-BB89AD434558","latestVersionIndicator":"Yes","beginDate":"2010-09-22","endDate":null,"createdBy":"MAESKEB","dateCreated":"2010-09-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"90D9E57A-FC1B-41F9-E040-BB89AD434558","beginDate":"2009-01-15","endDate":null,"createdBy":"MAESKEB","dateCreated":"2010-09-22","modifiedBy":"ONEDATA","dateModified":"2010-09-22","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2182370","version":"1","preferredName":"Procedures","preferredDefinition":"Tests, examinations, evaluations used to determine a subject's status or response to intervention.  ","longName":"PROCEDURES","context":"CCR","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D7049CF8-1252-211C-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-04-01","endDate":null,"createdBy":"DWARZEL","dateCreated":"2004-04-01","modifiedBy":"REEVESD","dateModified":"2004-09-24","changeDescription":"Created initially to support CCR value domain for CTMS. ","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2825158","version":"1","preferredName":"4-Hydroxytamoxifen Name","preferredDefinition":"A tamoxifen metabolite with both estrogenic and anti-estrogenic effects.  4-hydroxytamoxifen has a higher affinity for the estrogen receptor than tamoxifen, and functions as an antagonist in breast cancer cells. (NCI04):The words or language units by which a thing is known.","longName":"C975:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Afimoxifene","conceptCode":"C975","definition":"A tamoxifen metabolite with both estrogenic and anti-estrogenic effects.  Afimoxifene has a higher affinity for the estrogen receptor than tamoxifen, and functions as an antagonist in breast cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"608AA882-62CF-A8D3-E040-BB89AD4315E1","latestVersionIndicator":"Yes","beginDate":"2009-01-15","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-01-15","modifiedBy":"ONEDATA","dateModified":"2009-01-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"608AA882-62E0-A8D3-E040-BB89AD4315E1","latestVersionIndicator":"Yes","beginDate":"2009-01-15","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-01-15","modifiedBy":"MAESKEB","dateModified":"2010-11-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Test","type":"Preferred Question Text","description":"Test","url":null,"context":"DCP"}],"origin":"DCP:Division of Cancer Prevention","workflowStatus":"RELEASED","registrationStatus":"Application","id":"608AA882-6366-A8D3-E040-BB89AD4315E1","latestVersionIndicator":"Yes","beginDate":"2009-01-15","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-01-15","modifiedBy":"MAESKEB","dateModified":"2010-11-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}